C. Bokemeyer

1.6k citations

68 papers · 828 indexed · h-index 16

Impact in

Oncology top 10%
- Colorectal Cancer Treatments and Studies
- Cancer Treatment and Pharmacology
Pulmonary and Respiratory Medicine top 10%
- Renal cell carcinoma treatment
- Gastric Cancer Management and Outcomes
- Sarcoma Diagnosis and Treatment

Papers in ⓘ

Hematology 11
Genetics 9

Co-authors: Hans‐Joachim Schmoll (9 shared papers)Lothar Kanz (10 shared papers)A. Gerl (2 shared papers)J.T. Hartmann (3 shared papers)P. Koralewski (2 shared papers)U. Mengs (1 shared paper)Hilmar Stolte (2 shared papers)J. T. Hartmann (2 shared papers)
Journals: Journal of Clinical Oncology (23 papers)European Journal of Cancer (4 papers)Pharmacology (1 paper)JNCI Journal of the National Cancer Institute (1 paper)ESMO Open (1 paper)
Partner nations: Germany United Kingdom France

In The Last Decade

C. Bokemeyer

67 papers receiving 778 citations

Peers

Countries citing papers authored by C. Bokemeyer

Since Specialization

Citations

This map shows the geographic impact of C. Bokemeyer's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by C. Bokemeyer with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites C. Bokemeyer more than expected).

Fields of papers citing papers by C. Bokemeyer

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by C. Bokemeyer. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by C. Bokemeyer. The network helps show where C. Bokemeyer may publish in the future.

Co-authors

The 25 scholars most cited alongside C. Bokemeyer, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with C. Bokemeyer Line = papers co-authored together C. Bokemeyer links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Showing the 20 most-cited of 68 papers — load more, or switch the sort, to bring in the rest.

#	Work
1	Incidence of Metachronous Testicular Cancer in Patients With Extragonadal Germ Cell Tumors JNCI Journal of the National Cancer Institute ·J. T. Hartmann, S.D. Fosså, Craig R. Nichols, J.P. Droz, A. Horwich, A. Gerl, J. Beyer, J. Pont, Karim Fizazi, Hartmut Hecker, Lothar Kanz, Lawrence H. Einhorn, C. Bokemeyer	2001	121
2	Cetuximab plus 5-FU/FA/oxaliplatin (FOLFOX-4) versus FOLFOX-4 in the first-line treatment of metastatic colorectal cancer (mCRC): OPUS, a randomized phase II study Journal of Clinical Oncology ·C. Bokemeyer, Igor Bondarenko, А. Н. Махсон, J.T. Hartmann, Jorge Aparicio, Maria Giulia Zampino, S. Donea, Heinz Ludwig, Angela Zubel, P. Koralewski	2007	81
3	Metastatic seminoma treated with either single agent carboplatin or cisplatin-based combination chemotherapy: a pooled analysis of two randomised trials British Journal of Cancer ·C. Bokemeyer, Christian Kollmannsberger, Sally Stenning, J.T. Hartmann, A. Horwich, C. Clemm, A. Gerl, Christoph Meisner, C-P Rückerl, Hans‐Joachim Schmoll, Lothar Kanz, R.T.D. Oliver	2004	65
4	Cisplatin nephrotoxicity and protection by silibinin Nephrology Dialysis Transplantation ·J. Gaedeke, L. M. Fels, C. Bokemeyer, U. Mengs, Hilmar Stolte, H Lentzen	1996	58
5	Successful treatment of aTrichosporon beigelii septicemia in a granulocytopenic patient with amphotericin B and granulocyte colony-stimulating factor Infection ·Matthias Grauer, C. Bokemeyer, W. Bautsch, M. Freund, Hartmut Link	1994	34
6	Prognostic relevance of intracaval neoplastic extension for patients with renal cell cancer British Journal of Urology ·M.A. Kuczyk, C. Bokemeyer, Geoffrey P. Kohn, Christian G. Stief, S. Machtens, M. Truß, K. Höfner, Udo Jonas	1997	32
7	Interaction between <i>Helicobacter pylori and </i>Human Gastric Epithelial Cells in Culture: Effect of Antiulcer Drugs Pharmacology ·Siegfried Wagner, Winfried Beil, sup U.E.H. sup Mai, C. Bokemeyer, Hugo Meyer, M.P. Manns	1994	31
8	A European patient record study on diagnosis and treatment of chemotherapy-induced anaemia Supportive Care in Cancer ·H Ludwig, Matti Aapro, C. Bokemeyer, John A. Glaspy, Michael Hedenus, Timothy J. Littlewood, Anders Österborg, B. Rzychon, Daniell Mitchell, Yves Béguin	2014	31
9	Long term follow up in relapsed Hodgkin’s disease (HD): Updated results of the HD-R1 study comparing conventional chemotherapy (cCT) to high-dose chemotherapy (HDCT) with autologous haemopoetic stem cell transplantation (ASCT) of the German Hodgkin Study Group (GHSG) and the Working Party Lymphoma of the European Group for Blood and Marrow Transplantation (EBMT) Journal of Clinical Oncology ·Norbert Schmitz, Heinz Haverkamp, Andreas Josting, Volker Diehl, Beate Pfistner, Angelo Michele Carella, Matthias W. Haenel, F. Boissevain, C. Bokemeyer, A. H. Goldstone	2005	29
10	Predictive value of altered p27Kip1 and p21WAF/Cip1 protein expression for the clinical prognosis of patients with localized prostate cancer Oncology Reports ·M. Kuczyk, C. Bokemeyer, Julia Hartmann, Joke Schubach, CB Walter, S. Machtens, Robin Knuchel, C. Kollmannsberger, Udo Jonas, Jürgen Serth	2001	27
11	A phase I/II study of a stepwise dose-escalated regimen of cisplatin, etoposide and ifosfamide plus granulocyte-macrophage colony-stimulating factor (GM-CSF) in patients with advanced germ cell tumours European Journal of Cancer ·C. Bokemeyer, Hans‐Joachim Schmoll, A. Harstrick, H. J. Illiger, Bernd Metzner, U. Räth, J. Hohnloser, C. Clemm, Wolfgang E. Berdel, W. Siegert, U. Rüther, Helmut Ostermann, Michael Kneba, J. Hartlapp, M. Schröder, H. Poliwoda	1993	21
12	3004 ORAL Cetuximab plus 5-FU/FA/oxaliplatin (FOLFOX-4) in the first-line treatment of metastastic colorectal cancer (mCRC): a large-scale phase II study, OPUS European Journal of Cancer Supplements ·C. Bokemeyer, Elżbieta Starosławska, Anatoly Makhson, Igor Bondarenko, Julia Hartmann, Yu. A. Shelygin, О. П. Колеснік, Constantin Volovăț, Angela Zubel, P. Koralewski	2007	21
13	A LARGE OPEN-LABEL, NON-COMPARATIVE, PHASE III STUDY OF THE MULTI-TARGETED KINASE INHIBITOR SORAFENIB IN EUROPEAN PATIENTS WITH ADVANCED RENAL CELL CARCINOMA European Urology Supplements ·J. Thaddeus Beck, Elena Verzoni, S. Négrier, Ulrich Keilholz, Cezary Szczylik, Sergio Bracarda, C. Bokemeyer, D. J. Richel, Michael Staehler, Sabine Mersmann, K. Burock, Fredrik Erlandsson, Brandon Bernard	2008	17
14	High dose epirubicin in refractory or relapsed non-seminomatous testicular cancer: A phase II study Annals of Oncology ·A. Harstrick, Hans‐Joachim Schmoll, Hans‐Joachim Wilke, C. Schöber, M. Stahl, C. Wömpner, C. Bokemeyer, Gottfried Dölken, H. Poliwoda, K. Burk	1990	16
15	CT hepatic and splenic appearances with sarcoidosis European Journal of Radiology ·Christine Hoeffel, C. Bokemeyer, J C Hoeffel, H Gaucher, M. Galanski, Paul Fornés	1996	16
16	Phase I safety and pharmacology study of the EpCAM/CD3-bispecific BiTE antibody MT110 in patients with metastatic colorectal, gastric, or lung cancer. Journal of Clinical Oncology ·Walter Fiedler, Birgit Ritter, Ruth Seggewiss, C. Bokemeyer, Petra Fettes, Mark Klinger, Eva Vieser, Dominik Ruettinger, S. Kaubitzsch, M. Wolf	2010	15
17	Giant aneurysm causing frontal lobe syndrome Journal of Neurology ·C. Bokemeyer, Beryn Frank, Almuth Brandis, Wolfgang Weinrich	1990	14
18	Activating BRAF gene mutations are uncommon in hormone refractory prostate cancer in Caucasian patients Oncology Letters ·Jens Köllermann, HEIKO ALBRECHT, Thorsten Schlomm, Hartwig Huland, Markus Graefen, C. Bokemeyer, Richard H. Simon, Guido Sauter, Waldemar Wilczak	2010	13
19	Treatment of AdvancedGerm Cell Tumours byDose Intensified Chemotherapy withHaematopoietic Growth Factors orPeripheral Blood Stem Cells (PBSC) European Urology ·C. Bokemeyer, Hans‐Joachim Schmoll	1993	13
20	Use of the Comprehensive Geriatric Assessment (CGA) in elderly patients (pts) with solid tumors to predict mortality Journal of Clinical Oncology ·Friedemann Honecker, Ulrich Wedding, K. Rettig, Susanne Huschens, C. Bokemeyer	2009	13

About C. Bokemeyer

C. Bokemeyer is a scholar working on Hematology, Genetics, Oncology, Geriatrics and Gerontology and Pulmonary and Respiratory Medicine, having authored 68 papers that have together received 828 indexed citations. Recurring topics across this work include Testicular diseases and treatments (16 papers), Neuroblastoma Research and Treatments (8 papers), Renal cell carcinoma treatment (7 papers), Colorectal Cancer Treatments and Studies (7 papers), Cancer Genomics and Diagnostics (6 papers), Cancer Treatment and Pharmacology (5 papers), Gastric Cancer Management and Outcomes (5 papers) and Hepatocellular Carcinoma Treatment and Prognosis (4 papers). The work is most often cited by research in Oncology (268 citations), Pulmonary and Respiratory Medicine (299 citations), Hematology (84 citations), Neurology (103 citations) and Pathology and Forensic Medicine (121 citations). C. Bokemeyer has collaborated with scholars based in Germany, United Kingdom and France. Frequent co-authors include Hans‐Joachim Schmoll, Lothar Kanz, A. Gerl, J.T. Hartmann, P. Koralewski, U. Mengs, Hilmar Stolte, J. T. Hartmann, Igor Bondarenko and J. Beyer. Their work appears in journals such as Journal of Clinical Oncology, European Journal of Cancer, Pharmacology, JNCI Journal of the National Cancer Institute and ESMO Open.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact